Expanded Access of Investigational Drugs: The Experience of the Center of Drug Evaluation and Research Over a 10-Year Period

Benzer Materyaller

• Overview of FDA’s Expanded Access Program for Investigational Drugs
  Yazar:: Jarow, Jonathan P., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Ten-Year Experience for the Center for Drug Evaluation and Research, Part 2: FDA’s Role in Ensuring Patient Safety
  Yazar:: Jarow, Jonathan P., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Impact of Expanded Access on FDA Regulatory Action and Product Labeling
  Yazar:: Jarow, Jonathan P., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Access to Investigational Drugs: FDA Expanded Access Programs or “Right‐to‐Try” Legislation?
  Yazar:: Holbein, M. E. Blair, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Expanding Patient Access to Investigational Drugs: Single Patient Investigational New Drug and the “Right to Try”
  Yazar:: Van Norman, Gail A.
  Baskı/Yayın Bilgisi: (2018)